FDA Tianeptine Warning, SURMOUNT-5 Insights, and Social Prescribing Benefits

In this episode, Dr. Chi-Ming Chow opens with a discussion on the FDA's warning about "gas station heroin" and the risks associated with tianeptine use. He then compares tirzepatide and semaglutide, sharing insights from the SURMOUNT-5 trial. The episode continues with findings from the BedMed trial, exploring the impact of timing on antihypertensive medication efficacy. Dr. Chow also delves into bedtime listening habits, offering strategies for improving sleep. The concept of social prescribing is introduced, highlighting its benefits and potential to tackle loneliness and societal issues. The episode concludes with a summary and wrap-up of key points.

G
You're chatting with AI hosts.
- / -